These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 23278995

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. More than a decade of international experience with a pdFVIII/VWF concentrate in immune tolerance.
    Santagostino E.
    Haemophilia; 2013 Jan; 19 Suppl 1():8-11. PubMed ID: 23278994
    [Abstract] [Full Text] [Related]

  • 3. Immune tolerance induction in patients with hemophilia A.
    Astermark J.
    Thromb Res; 2011 Jan; 127 Suppl 1():S6-9. PubMed ID: 21056905
    [Abstract] [Full Text] [Related]

  • 4. Epidemiology of inhibitors and current treatment strategies.
    Kreuz W, Ettingshausen CE, Auerswald G, Saguer IM, Becker S, Funk M, Heller C, Klarmann D, Klingebiel T, GTH PUP Study Group.
    Haematologica; 2003 Jun; 88(6):EREP04. PubMed ID: 12826530
    [Abstract] [Full Text] [Related]

  • 5. First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study.
    Kreuz W, Escuriola Ettingshausen C, Vdovin V, Zozulya N, Plyushch O, Svirin P, Andreeva T, Bubanská E, Campos M, Benedik-Dolničar M, Jiménez-Yuste V, Kitanovski L, Klukowska A, Momot A, Osmulskaya N, Prieto M, Šalek SZ, Velasco F, Pavlova A, Oldenburg J, Knaub S, Jansen M, Belyanskaya L, Walter O, ObsITI study group, ObsITI committee.
    Haemophilia; 2016 Jan; 22(1):87-95. PubMed ID: 26202305
    [Abstract] [Full Text] [Related]

  • 6. ITI choice for the optimal management of inhibitor patients - from a clinical and pharmacoeconomic perspective.
    Oldenburg J, Austin SK, Kessler CM.
    Haemophilia; 2014 Sep; 20 Suppl 6():17-26. PubMed ID: 24975701
    [Abstract] [Full Text] [Related]

  • 7. Immune tolerance: critical issues of factor dose, purity and treatment complications.
    DiMichele DM.
    Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
    [Abstract] [Full Text] [Related]

  • 8. Use of Haemate(®) P as immune tolerance induction in patients with severe haemophilia A who failed previous induction attempts: a multicentre observational study.
    Rothschild C, D'Oiron R, Borel-Derlon A, Gruel Y, Navarro R, Negrier C.
    Haemophilia; 2013 Mar; 19(2):281-6. PubMed ID: 23038998
    [Abstract] [Full Text] [Related]

  • 9. Primary and rescue immune tolerance induction in children and adults: a multicentre international study with a VWF-containing plasma-derived FVIII concentrate.
    Oldenburg J, Jiménez-Yuste V, Peiró-Jordán R, Aledort LM, Santagostino E.
    Haemophilia; 2014 Jan; 20(1):83-91. PubMed ID: 24354480
    [Abstract] [Full Text] [Related]

  • 10. The role of VWF for the success of immune tolerance induction.
    Kreuz W.
    Thromb Res; 2008 Jan; 122 Suppl 2():S7-S12. PubMed ID: 18549910
    [Abstract] [Full Text] [Related]

  • 11. New protocol for immune tolerance induction in acquired hemophilia.
    Nemes L, Pitlik E.
    Haematologica; 2000 Oct; 85(10 Suppl):64-8. PubMed ID: 11187874
    [Abstract] [Full Text] [Related]

  • 12. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC, Liao YM, Tsai SP, Chang TT.
    Pediatr Blood Cancer; 2011 Dec 01; 57(6):1029-33. PubMed ID: 21793191
    [Abstract] [Full Text] [Related]

  • 13. New predictive approaches for ITI treatment.
    Minno GD, Santagostino E, Pratt K, Königs C.
    Haemophilia; 2014 Sep 01; 20 Suppl 6():27-43. PubMed ID: 24975702
    [Abstract] [Full Text] [Related]

  • 14. VWF/FVIII concentrates in high-risk immunotolerance: the RESIST study.
    Gringeri A.
    Haemophilia; 2007 Dec 01; 13 Suppl 5():73-7. PubMed ID: 18078402
    [Abstract] [Full Text] [Related]

  • 15. Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units.
    Ter Avest PC, Fischer K, Gouw SC, Van Dijk K, Mauser-Bunschoten EP.
    Haemophilia; 2010 May 01; 16(102):71-9. PubMed ID: 20536988
    [Abstract] [Full Text] [Related]

  • 16. The role of plasma-derived factor VIII/von Willebrand factor concentrates in the treatment of hemophilia A patients.
    Auerswald G, Spranger T, Brackmann HH.
    Haematologica; 2003 Jun 01; 88(6):EREP05. PubMed ID: 12826531
    [Abstract] [Full Text] [Related]

  • 17. The use of factor VIII/von Willebrand factor concentrate for immune tolerance induction in haemophilia A patients with high-titre inhibitors: association of clinical outcome with inhibitor epitope profile.
    Greninger DA, Saint-Remy JM, Jacquemin M, Benhida A, DiMichele DM.
    Haemophilia; 2008 Mar 01; 14(2):295-302. PubMed ID: 18081826
    [Abstract] [Full Text] [Related]

  • 18. Immune tolerance induction with a high purity von Willebrand factor/VIII complex concentrate in haemophilia A patients with inhibitors at high risk of a poor response.
    Gringeri A, Musso R, Mazzucconi MG, Piseddu G, Schiavoni M, Pignoloni P, Mannucci PM, RITS-FITNHES Study Group.
    Haemophilia; 2007 Jul 01; 13(4):373-9. PubMed ID: 17610550
    [Abstract] [Full Text] [Related]

  • 19. Successful immune tolerance induction with high-dose coagulation factor VIII and intravenous immunoglobulins in a patient with congenital hemophilia and high-titer inhibitor of coagulation factor VIII despite unfavorable prognosis for the therapy.
    Kubisz P, Plamenová I, Hollý P, Stasko J.
    Med Sci Monit; 2009 Jun 01; 15(6):CS105-11. PubMed ID: 19488019
    [Abstract] [Full Text] [Related]

  • 20. Low-dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors.
    Unuvar A, Kavakli K, Baytan B, Kazanci E, Sayli T, Oren H, Celkan T, Gursel T.
    Haemophilia; 2008 Mar 01; 14(2):315-22. PubMed ID: 18081830
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.